Funding for HIV prevention research and development (R&D) is crucial for continued innovation in the field. Tracking this funding, its volume, direction and source, makes it possible to address opportunities and gaps, hold the global community accountable to its promises, and sustain forward momentum in the fight to end the epidemic.
- HIV Prevention Research & Development Investments, 2000-2015; full report
- HIV Prevention Research & Development Investments, 2000-2015; 1-pager
In 2015, global funding for HIV prevention R&D declined slightly, from US$1.25 billion in 2014 to US$1.20 billion. This continues a decade of roughly flat funding. The US public sector remained the largest global contributor at US$850 million, and together with the Bill & Melinda Gates Foundation (BMGF), the largest philanthropic funder, constituted 81 percent of all funding.
Funding towards preventive AIDS vaccines and female condoms increased two percent and 63 percent respectively, while investments towards microbicides, PrEP, TasP, VMMC and PMTCT declined by eight percent, 40 percent, 17 percent 75 percent and 10 percent respectively.
While it remained the largest source of investment, the US public sector decreased its investment by 2.1 percent. Contributions from European governments remained the same as 2014 at $69 million, 6 percent of all funding. Investment from other countries outside the US and Europe fell to US$50 million from US$52 million (4 percent of the total).
Philanthropic funding was also in a decline in 2015, falling to US$157 million, a 22 percent decrease from 2014. The number of funders increased however, but it was not enough to offset reductions in funding from the BMGF (24 percent reduction) and Wellcome Trust (41 percent reduction), traditionally the two largest philanthropic donors.
Finally, estimated contributions from the commercial sector increased by 18 percent in 2015.
Other key findings of the 2015 funding analysis include:
- Investment is being made along all phases of the research pipeline, with an increasing emphasis on the science of delivery, or implementation research.
- Industry is expanding its contributions to HIV prevention R&D, not just through cash alone, but also technical expertise and product donations in critical areas.
- Funding remains concentrated among a small number of large investors, imperiling funding continuity should one of these funders drop out or make significant reductions.
- Global funding commitments have not yet translated into action, and for real achievement to be made toward ending the HIV epidemic, HIV prevention R&D must regain and retain prominence on the development agenda.
- Continued mobilization of middle and lower-middle income country resources is imperative. These countries must be supported in their efforts.